Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous hematopoietic stem cells (University of Florida, f24a6a)
- Development stage
- Unknown
- Lead developer
- University of Florida
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous hematopoietic stem cells (HSCs) are utilized as a supportive cellular therapy within the ACTION trial (Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas), an investigational study conducted by the University of Florida. In this protocol, patients with newly-diagnosed pediatric high-grade gliomas (WHO Grade III or IV) undergo mobilized leukapheresis to collect peripheral blood stem cells (PBSCs) prior to receiving dose-intensified temozolomide (TMZ) chemotherapy. Following the intensive chemotherapy cycles, the autologous HSCs are re-infused to facilitate hematopoietic recovery and mitigate the severe myelosuppression caused by the treatment. This hematopoietic rescue is a critical component of the multi-modal treatment strategy, which also includes the administration of tumor total RNA-loaded dendritic cell (TTRNA-DC) vaccines and tumor-specific T cells (TTRNA-xALT) to stimulate an anti-tumor immune response.
- Other names
- autologous peripheral blood stem cellsHSCsPBSCs
Beyond the preview
Go deeper on autologous hematopoietic stem cells (University of Florida, f24a6a).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous hematopoietic stem cells (University of Florida, f24a6a).